01
Potential research areas
Sanctions, regulatory warnings, enforcement, fraud alerts, insolvency, company inconsistencies, aliases, adverse information and transaction warning indicators.
Counterparty risk intelligence
Blacklist and Grey-List Counterparty Screening
Distinguish authoritative warnings, substantiated findings and indicators requiring enhanced review through source-led counterparty screening support.
Request a service assessmentTBH / BLACKLIST AND GREY-LIST COUNTERPARTY SCREENINGSTRUCTURE • CONTROL • PROGRESS
02
Careful language
Reported, alleged, unresolved, disputed, subject to verification and enhanced review recommended are used where evidence requires qualification.
03
Decision support
Assess findings alongside independent legal, regulatory and commercial advice appropriate to the transaction.
STRUCTURE. PROTECT. PROGRESS.
Choose the next appropriate step.
DiscordPractical scope and preparation guidance
Scope and information needed
Provide the legal name, registration jurisdiction, role, authority records and the question requiring review. Identify which people or entities the evidence actually concerns.
Source hierarchy and identity uncertainty
Distinguish official warnings, substantiated findings, private reports and allegations. Record source, date, jurisdiction and matching evidence. Blacklist indicators warrant careful qualification; grey-list indicators call for further review.
Review outputs and limitations
The scoped review records findings, gaps and follow-up actions. No public live screening database or universal commodity registry is supplied here. Absence of an adverse result is not proof of safety, and disputed information is not established wrongdoing.